Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite-Reference-Cited by-同舟云学术

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite

Published:2016-11-18 Issue:3 Volume:40 Page:382-390
ISSN:0253-6269
Container-title:Archives of Pharmacal Research
language:en
Short-container-title:Arch. Pharm. Res.

Author:

Kim Se-Hyung,Kim Do-Hoon,Byeon Ji-Yeong,Kim Young-Hoon,Kim Dong-Hyun,Lim Hye-Jin,Lee Choong-Min,Whang Sang Sup,Choi Chang-Ik,Bae Jung-Woo,Lee Yun Jeong,Jang Choon-Gon,Lee Seok-Yong

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,Drug Discovery,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12272-016-0861-2.pdf

Reference47 articles.

1. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60:418–422

2. Bae JW, Choi CI, Jang CG, Lee SY (2011a) Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71:550–555

3. Bae JW, Choi CI, Kim MJ, Oh DH, Keum SK, Park JI, Kim BH, Bang HK, Oh SG, Kang BS, Park HJ, Kim HD, Ha JH, Shin HJ, Kim YH, Na HS, Chung MW, Jang CG, Lee SY (2011b) Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32:1303–1308

4. Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY (2012) Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. Int J Clin Pharmacol Ther 50:683–689

5. Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U (2003) Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 42:283–292

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes;Archives of Pharmacal Research;2023-12

2. Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome <i>P450 2C9*3</i> Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database;Biological and Pharmaceutical Bulletin;2023-06-01

3. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects;Archives of Pharmacal Research;2023-04-25

4. Novel naphthalene-derived coumarin composites: synthesis, antibacterial, and antifungal activity assessments;EURASIAN CHEM COMMUN;2022

5. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes;Archives of Pharmacal Research;2022-08